Sam Altman, CEO of OpenAI, recently stated that OpenAI may consider investing in or subsidizing companies that extensively apply its AI technology for new drug development. Altman revealed this at the Cisco Systems AI Conference in San Francisco, saying that such investments could not only promote advancements in medical research but also bring substantial returns to OpenAI.

Altman pointed out that as the importance of AI technology in scientific exploration continues to grow, the pharmaceutical industry urgently needs funding to drive cutting-edge research. He said that OpenAI may collaborate with pharmaceutical companies, covering the costs of using its AI models, and would receive a percentage of royalties from new drugs or therapies developed by these companies. He mentioned that although no specific cooperation has been reached yet, the potential of OpenAI in this area is significant.

This statement indicates that OpenAI is planning to achieve scientific breakthroughs through investment and collaboration, thereby generating revenue in the market. Altman emphasized that for customers who call its models via OpenAI's API, OpenAI will not charge a share of the results, and all related R&D outcomes will belong entirely to the customers. He believes that this collaboration model can benefit more companies without affecting the user experience for ordinary users.

As tech giants like OpenAI, Google, and Anthropic increase their presence in the fields of science and healthcare, the application scenarios of AI technology are rapidly expanding. From new drug development to personal medical data analysis, the future potential is undoubtedly enormous.

In conclusion, OpenAI's layout in the field of AI pharmaceuticals will bring new opportunities to the industry and also open up new revenue models for its own sustainable development.